valemetostat tosylate + pembrolizumab
Phase 1/2Recruiting 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer, Lung Cancer
Trial Timeline
Oct 30, 2024 → Apr 30, 2030
NCT ID
NCT06644768About valemetostat tosylate + pembrolizumab
valemetostat tosylate + pembrolizumab is a phase 1/2 stage product being developed by Daiichi Sankyo for Non-small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06644768. Target conditions include Non-small Cell Lung Cancer, Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Non-small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06644768 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Non-small Cell Lung Cancer